Personalizing prophylactic surgery in cancer: Current practice and future perspectives from new genome-wide association studies

Expert Review of Anticancer Therapy

Volumn 11, Issue 6, 2011, Pages 813-816

  Zoras, Odysseas ^a   Katsios, Christos S ^b   Roukos, Dimitrios H ^b,c  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

cancer; genetics; genomics; personal risks; prevention; prophylactic surgery

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; UVOMORULIN;

BRCA2 GENE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SURGERY; E CADHERIN GENE; EVIDENCE BASED PRACTICE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOME ANALYSIS; HIGH RISK PATIENT; HIGH RISK POPULATION; MLH1 GENE; MSH2 GENE; MSH6 GENE; ONCOGENE; PERSONALIZED MEDICINE; PREVENTIVE MEDICINE; PRIMARY PREVENTION; PROCESS OPTIMIZATION; REVIEW; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURGICAL RISK; TREATMENT PLANNING; TUMOR GENE;

GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PRIMARY PREVENTION;

EID: 79959776012     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.22     Document Type: Review

References (24)

1. Feero WG, Guttmacher AE, Collins FS. Genomic medicine - an updated primer. N. Engl. J. Med. 362(21), 2001-2011 (2010
2. Hamburg MA, Collins FS. The path to personalized medicine. N. Engl. J. Med. 363(4), 301-304 (2010
3. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 4, 665-676 (2004 (Pubitemid 39215065)
4. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin. Genet. 76(1), 1-18 (2009
5. Guilford P, Hopkins J, Harraway J et al. E-cadherin germline mutations in familial gastric cancer. Nature 392(6674), 402-405 (1998 (Pubitemid 28168738)
6. Domchek SM, Friebel TM, Singer CF et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9), 967-975 (2010
7. Guillem JG, Wood WC, Moley JF et al.; ASCO; SSO. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J. Clin. Oncol. 24(28), 4642-4660 (2006 (Pubitemid 46630963)
8. National Comprehensive Cancer Network. Guidelines for treatment of cancer by site. National Comprehensive Cancer Network, PA, USA (2009
9. Manolio TA, Collins FS, Cox NJ. Finding the missing heritability of complex diseases. Nature 461(7265), 747-753 (2009
10. Manolio TA. Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 363(2), 166-176 (2010
11. Wacholder S, Hartge P, Prentice R et al. Performance of common genetic variants in breast-cancer risk models. N. Engl. J. Med. 362(11), 986-993 (2010
12. Travis RC, Reeves GK, Green J et al. Million Women Study Collaborators: gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study. Lancet 375(9732), 2143-2151 (2010
13. Pruthi S, Gostout BS, Lindor NM. Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Mayo Clin. Proc. 85(12), 1111-1120 (2010
14. Metcalfe KA, Finch A, Poll A et al. Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. Br. J. Cancer. 100(2), 421-425 (2009
15. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893-2917 (2010
16. Landsbergen KM, Brunner EG, Manders P, Hoogerbrugge N, Prins JB. Educational-support groups for BRCA mutation carriers satisfy need for information but do not affect emotional distress. Genet. Counsel. 21(4), 423-437 (2010
17. Park JH, Wacholder S, Gail MH et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat. Genet. 42(7), 570-575 (2010
18. Altshuler DM, Gibbs RA, Peltonen L et al.; International HapMap 3 Consortium. Integrating common and rare genetic variation in diverse human populations. Nature 467(7311), 52-58 (2010
19. Baker M. Genomics: the search for association. Nature 467(7319), 1135-1138 (2010
20. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer 2(5), 331-341 (2002 (Pubitemid 37328946)
21. Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature 461(7261), 218-223 (2009
22. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 9(10), 775-789 (2010
23. Hudson TJ, Anderson W, Artez A et al. International network of cancer genome projects. Nature 464, 993-998 (2010
24. No authors listed. Time for the epigenome. Nature 463(7281), 587 (2010).